Online portal launched to combat urgent need for more accessible ways to identify trial participants

Clinical-Trial-Media-launches-online-portal-for-studies-and-trials.jpg

An online portal enabling people worldwide to find and express interest in clinical trials has been launched by Clinical Trial Media, a clinical trial participant recruitment and retention company.

The company works with pharmaceutical companies through all stages of clinical research made the announcement earlier this month (January 2024).

The new portal enables people to learn how to get involved in the research process and get matched with appropriate studies. Clinical Trial Media says this will help its part in bringing critical therapies and medical devices to market.

In its research, the company found that human studies are the most expensive and time-consuming part of the drug development process. It has spent 25 years populating and overseeing participant retention in trials for some of the most ground-breaking drug releases by major pharmaceutical companies.

Two million interested in clinical studies 

Having recruited for more than 2,000 trials, the company has built a database of more than two million people interested in participating in clinical studies. However it says millions of others might qualify for trial participation, but either don’t know where to find out about them or don’t understand what’s involved in the clinical research process.

Through ExploreClinicalResearch.com, the aim is to help fill these gaps by making it easier for people unfamiliar with clinical research to find trials they or their loved ones might match with, while also educating them about the process.

The company is currently seeking participants for clinical trials across approximately 20 adult and pediatric therapeutic areas, ranging from autoimmune diseases and Alzheimer’s to diabetes, obesity, excess weight and others. It has additionally identified over 50 other health conditions for potential future trials, that portal visitors are invited to express interest in.

Explore Clinical Research will make it easier for potential trial participants to learn about and enroll by enabling potential participants to share relevant health conditions for current and future trials.

Visitors complete a six-step survey where they share their basic identifying information and their preference for adult and/or pediatric trials. They’re additionally prompted to select any health conditions that are relevant to them or a loved one, from a list that currently includes, but is not limited to, Alzheimer’s, Parkinson’s, type-2 diabetes, heart disease, amyotrophic lateral sclerosis (ALS), lupus, arthritis, and psoriasis.

Quickly populate clinical research

It can match individuals with trials to quickly populate clinical research, equipped with participants’ information and areas of interest, the company can now more quickly match them with relevant trials, within their preferred regions. At this point, participants can decide if they are interested in learning more and ultimately volunteering.

Educating future and existing participants about the clinical trial process is another aim as it can take years to recruit participants in a trial process that can cost over a billion dollars from drug discovery to rollout. The more informed individuals are, the more likely they are to participate and complete each stage they are enrolled in. By visiting ExploreClinicalResearch.com, potential participants can learn more about the research process before it starts and gain a clear understanding of why clinical research that brings critical drugs to market is not possible without their participation.

“Considering that there are 450,000+ clinical trials in progress around the world right now–and that 80% of them will be delayed because pharmaceutical companies can’t find enough volunteers to participate–there is an urgent need for more accessible ways to identify potential participants,” said Cara Brant, CEO of Clinical Trial Media.

“We regularly have individuals request information about other trials, which communicates that the need for participants isn’t due to a lack of interest, but a lack of knowledge and access. We are working to change this.”